ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR), a commercial stage oncology company, announced today that a record number of abstracts focusing on Tumor Treating Fields (TTFields) were accepted and will be presented at the 20th Annual Meeting of the Society for Neuro-Oncology on Nov. 19-22 in San Antonio, including oral presentations of two new analyses of the EF-14 superiority data for Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma (GBM).
Help employers find you! Check out all the jobs and post your resume.
